Go Pro

Genus (LON:GNS) Releases Earnings Results

Genus logo with Consumer Discretionary background
Image from MarketBeat Media, LLC.

Key Points

  • FY 2026 performance was strong: adjusted profit before tax and adjusted EPS rose 35%, free cash flow reached £62 million, and leverage declined to 0.4x.
  • Genus announced a £60 million share buyback and recommended a 10% dividend increase to 35.2 pence per share, while PIC delivered broad-based growth and gained market share.
  • FY 2027 growth is expected to be moderate and weighted toward the second half, reflecting weak agricultural markets, disease pressures, softer dairy conditions, and higher PRP and development costs.
  • Interested in Genus? Here are five stocks we like better.

Genus (LON:GNS - Get Free Report) announced its earnings results on Thursday. The company reported GBX 110.30 EPS for the quarter, Digital Look Earnings reports. Genus had a return on equity of 44.90% and a net margin of 43.35%.

Here are the key takeaways from Genus' conference call:

  • FY 2026 results were strong: adjusted profit before tax and adjusted EPS each rose 35%, while free cash flow increased to £62 million and leverage fell to 0.4x.
  • Genus announced a £60 million share buyback for FY 2027 and recommended a 10% increase in the full-year dividend to 35.2 pence per share, reflecting confidence in cash generation and future growth.
  • PIC delivered broad-based growth, including 52% royalty-revenue growth in China and market-share gains, while the new China joint venture is expected to support further expansion in the world’s largest porcine market.
  • PRP regulatory progress continued with approvals or favorable determinations in Argentina, Canada, Uruguay, and Peru; commercialization is now beginning in selected Latin American markets, although approvals in Mexico and China remain pending.
  • Management expects FY 2027 underlying adjusted profit before tax to be only moderately higher, with growth weighted toward the second half due to weak agricultural markets, North American disease pressures, lower Brazilian growth, depressed dairy conditions, and higher PRP and product-development costs.

Genus Stock Up 1.5%

Shares of GNS stock traded up GBX 32 during mid-day trading on Friday, reaching GBX 2,192. 3,602,064 shares of the company were exchanged, compared to its average volume of 785,822. The company has a debt-to-equity ratio of 14.02, a quick ratio of 1.08 and a current ratio of 2.22. The business's 50 day simple moving average is GBX 2,220.31 and its 200 day simple moving average is GBX 2,374.09. The company has a market capitalization of £1.46 billion, a P/E ratio of 30.87, a P/E/G ratio of 2.87 and a beta of 0.90. Genus has a fifty-two week low of GBX 1,943 and a fifty-two week high of GBX 3,220.

Trending Headlines about Genus

Here are the key news stories impacting Genus this week:

  • Positive Sentiment: Genus reported higher FY26 pretax profit, reduced leverage and launched a £60 million share buyback. The repurchase signals management confidence in the company’s long-term growth prospects and could support earnings per share. Genus Launches £60 Mln Share Buyback Programme
  • Positive Sentiment: Berenberg reaffirmed its Buy rating and set a GBX 3,350 price target, implying substantial upside from recent trading levels. Genus announces £60m buyback as FY profits rise
  • Neutral Sentiment: Genus posted quarterly EPS of GBX 110.30, with a 9.70% return on equity and 7.07% net margin. The results provide evidence of profitability, but the market reaction indicates investors were more concerned about forward guidance and revenue performance. Genus quarterly earnings
  • Negative Sentiment: Management forecast moderate FY27 operating-profit growth, while FY26 revenue missed expectations. The combination has raised concerns about slower near-term momentum, outweighing the improved profit, lower debt and buyback news. Genus Shares Fall as Company Forecasts Moderate FY27 Growth

Insider Transactions at Genus

In related news, insider Celia Baxter purchased 2,336 shares of the business's stock in a transaction that occurred on Friday, June 26th. The shares were purchased at an average cost of GBX 2,140 per share, with a total value of £49,990.40. 0.71% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank restated a "buy" rating and set a GBX 3,350 target price on shares of Genus in a research note on Thursday. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of GBX 3,216.67.

Check Out Our Latest Report on GNS

Genus Company Profile

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.

Featured Stories

Should You Invest $1,000 in Genus Right Now?

Before you consider Genus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.

While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines